Publications by authors named "Boris Juelg"

Article Synopsis
  • Gardasil® and Cervarix® vaccines protect against HPV16 and HPV18, which are responsible for about 70% of cervical cancers, by generating high levels of neutralizing antibodies.
  • Both vaccines prevent the progression of cervical intraepithelial neoplasia grade 2 and higher (CIN2+), with Cervarix® offering enhanced protection.
  • Systems serology analysis shows that while both vaccines activate strong immune responses, Cervarix® notably induces more IgG3 and better overall coordination between responses to HPV16 and HPV18, likely due to different adjuvants used in the formulations.
View Article and Find Full Text PDF

Rapid diagnostics that can accurately inform patients of disease risk and protection are critical to mitigating the spread of the current COVID-19 pandemic and future infectious disease outbreaks. To be effective, such diagnostics must rely on simple, cost-effective, and widely available equipment and should be compatible with existing telehealth infrastructure to facilitate data access and remote care. Commercial glucometers are an established detection technology that can overcome the cost, time, and trained personnel requirements of current benchtop-based antibody serology assays when paired with reporter molecules that catalyze glucose conversion.

View Article and Find Full Text PDF

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coupled with a lack of therapeutics, has paralyzed the globe. Although significant effort has been invested in identifying antibodies that block infection, the ability of antibodies to target infected cells through Fc interactions may be vital to eliminate the virus. To explore the role of Fc activity in SARS-CoV-2 immunity, the functional potential of a cross-SARS-reactive antibody, CR3022, was assessed.

View Article and Find Full Text PDF

Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117,a broad and potent neutralizing antibody against the CD4 binding site of the HIV-1 Env protein, during analytical treatment interruption in 13 HIV-1-infected individuals. Participants with 3BNC117-sensitive virus outgrowth cultures were enrolled.

View Article and Find Full Text PDF

The dissemination of HIV from an initial site of infection is facilitated by motile HIV-infected CD4(+) T-cells. However, the impact of infected target cell migration on antigen recognition by HIV-specific CD8(+) T-cells is unclear. Using a 3D in vitro model of tissue, we visualized dynamic interactions between HIV-infected or peptide-pulsed CD4(+) T-cells and HIV-specific CD8(+) T-cells.

View Article and Find Full Text PDF